Trilaciclib dihydrochlorideProduct ingredient for Trilaciclib
- Name
- Trilaciclib dihydrochloride
- Drug Entry
- Trilaciclib
Trilaciclib, or G1T28, is a CDK4 and CDK6 inhibitor, indicated to reduce the incidence of chemotherapy induced myelosuppression in patients before topotecan-containing or platinum and etoposide-containing chemotherapy for extensive stage small cell lung cancer.6 CDK4 and CDK6 inhibitors have been investigated since the mid 1990s for their use in tumorigenesis and chemotherapy.3 Trilaciclib was first described in the literature in 2016.1
Trilaciclib was granted FDA approval on 12 February 2021.5
- Accession Number
- DBSALT003163
- Structure
Structure for Trilaciclib dihydrochloride (DBSALT003163)
- Synonyms
- Not Available
- External IDs
- G1T28 dihydrochloride
- UNII
- 4BX07W725T
- CAS Number
- 1977495-97-8
- Weight
- Average: 519.48
Monoisotopic: 518.2076131 - Chemical Formula
- C24H32Cl2N8O
- InChI Key
- BRCYOXKEDFAUSA-UHFFFAOYSA-N
- InChI
- InChI=1S/C24H30N8O.2ClH/c1-30-9-11-31(12-10-30)18-5-6-20(25-15-18)28-23-26-14-17-13-19-22(33)27-16-24(7-3-2-4-8-24)32(19)21(17)29-23;;/h5-6,13-15H,2-4,7-12,16H2,1H3,(H,27,33)(H,25,26,28,29);2*1H
- IUPAC Name
- 12'-{[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino}-2',5',11',13'-tetraazaspiro[cyclohexane-1,3'-tricyclo[7.4.0.0^{2,7}]tridecane]-1'(9'),7',10',12'-tetraen-6'-one dihydrochloride
- SMILES
- Cl.Cl.CN1CCN(CC1)C1=CN=C(NC2=NC3=C(C=C4N3C3(CCCCC3)CNC4=O)C=N2)C=C1
- External Links
- ChemSpider
- 64854796
- Predicted Properties
Property Value Source logP 2.74 Chemaxon pKa (Strongest Acidic) 11.59 Chemaxon pKa (Strongest Basic) 7.65 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 7 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 91.21 Å2 Chemaxon Rotatable Bond Count 3 Chemaxon Refractivity 128.51 m3·mol-1 Chemaxon Polarizability 50.51 Å3 Chemaxon Number of Rings 6 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon